{"entity":{"id":"endogenous-promoter-payload-control","kind":"term","name":"Control of cell payloads by endogenous promoters","aka":["NR4A2 cytokine payload control","RGS16 cytokine payload control","activation-responsive cytokine expression"],"tldr":"An engineered cell can place a payload under the control of a naturally regulated gene. The resulting expression pattern still needs measurement in the actual cells and tissues.","summary":"A CRISPR knock-in can connect an engineered cytokine payload to regulatory control at an endogenous gene locus. In preclinical work, NR4A2 and RGS16 control supported cytokine expression in specified CAR T-cell settings, with tumor and safety measurements in mouse models. This is distinct from adding synthetic response elements to a separate promoter. Neither the locus name nor an activation-responsive design proves tumor-only secretion, clinical safety or patient benefit.","asOf":"2026-11-08","links":[{"label":"Chen et al.: endogenous-locus control of cytokine payloads in preclinical models (2025)","url":"https://pubmed.ncbi.nlm.nih.gov/40604285/"},{"label":"Guo et al.: synthetic NR4A-responsive payload promoter in human-cell experiments (2022)","url":"https://pubmed.ncbi.nlm.nih.gov/35316028/"},{"label":"Zhang et al.: inducible IL-12 TIL study and systemic toxicity (2015)","url":"https://pubmed.ncbi.nlm.nih.gov/25695689/"}],"tags":[],"related":["armored-car","gene-regulatory-elements","cellular-kinetics-and-persistence"],"cancers":[],"sections":["cell-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Chen and colleagues screened endogenous genes and investigated NR4A2/RGS16 regulation for payloads including IL-12 and IL-2 in cell and mouse models. Patient-derived cells were also studied experimentally; that is not a clinical treatment result in those patients. The edited locus, retained native gene function, off-state expression, inducibility and persistence need characterization.","Guo and colleagues instead tested a synthetic NR4A-responsive promoter against a conventional NFAT-responsive promoter in human-cell experiments with weak stimulation. Reporter expression and improved proliferation in that system do not establish a clinical potency or safety ranking, and the synthetic promoter is distinct from an endogenous NR4A2-locus knock-in.","Keep trigger recognition, payload transcription, secretion, tissue distribution and downstream activity separate. The IL-12 TIL clinical experience shows why inducible production alone cannot establish confinement or freedom from systemic toxicity. Viable producer-cell abundance, time and cell state matter alongside cytokine concentration."],"category":"Treatment jargon"},"route":"/terms/endogenous-promoter-payload-control/","neighbours":{"technology":[{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/"}],"term":[{"id":"cellular-kinetics-and-persistence","kind":"term","name":"Cellular kinetics and persistence","route":"/terms/cellular-kinetics-and-persistence/"},{"id":"gene-regulatory-elements","kind":"term","name":"Promoters, enhancers and transcription factors","route":"/terms/gene-regulatory-elements/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}]}}